Biochemical signature in Alzheimer’s disease

Abstract

Alzheimer's disease (AD) is the most common cause of dementia in the elderly. The lack of a definitive treatment or cure for AD puts a significant financial strain on health care systems. As part of its clinical profile, AD involves progressive memory loss and deficits in one or more cognitive domains, including aphasia (language disturbance), agnosia (inability to recognize people or objects in the presence of intact sensory function), apraxia (inability to perform motor acts while the motor system is intact), or executive function (organize, sequence actions or form abstraction). They represent a significant decline in earlier levels of functioning in AD patients that can interfere with daily life or work [1] .